Biopharma News

Eli Lilly will present early-stage data regarding cancer therapies at AACR 2014.

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

European scientists have discovered a method to improve the efficiency of the pharmaceutical production through plant biotechnology.

New research finds that recurrent head and neck tumors have gene mutations that could be vulnerable to the cancer drug dasatinib.

Immunovaccine reports enhanced cancer vaccine combination therapies at 2014 AACR Annual Meeting.

Sanofi and Genzyme to resubmit FDA application for approval of Lemtrada, for the treatment of relapsing forms of multiple sclerosis.

Novartis delivers 2 million treatments of its pediatric antimalarial to Zambia in collaboration with Malaria No More's Power of One campaign.

Baxter announces plans to split into two independent companies by mid-2015.

FDA approves Xolair (omalizumab) for the treatment of a rare skin disease known as chronic idiopathic urticarial.

Cobra Biologics and BioCancell announce an agreement to manufacture BioCancell's BC-821 cancer drug.

Novartis calls for more research to understand and find treatments for rare disease.

Debiopharm acquires Affinium's clinical and preclinical assets and its technology platform.

PharmaCell enters an agreement purchase TiGenix therapy production facility.

Teva announced an agreement to acquire NuPathe and its migraine treatment patch.

The Natural Product Center of Excellence seeks to identify novel active compounds for new antibiotics.

J&J's diagnostics business goes to global asset manager, The Carlyle Group.

CCBR–SYNARC and BioClinica merge to create a provider of specialized outsourced clinical services.

CytomX Therapeutics and ImmunoGen announce collaboration to develop probody-drug conjugate therapies for the treatment of cancer.

Research was published describing a natural interferon-alpha for infection control and treatment of drug-resistant H7N9 influenza.

Zymeworks has entered into a licensing and collaboration agreement with ImClone Systems to develop novel bi-specific antibody oncology therapeutics.

Genzyme plans to appeal FDA?s decision that the multiple-sclerosis treatment is not ready for approval.

Pfizer appoints management changes to take effect in 2014.

Siemens enters agreement with Pfizer to commercialize diagnostic tests for therapeutic products across Pfizer's pipeline.

ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.

AstraZeneca's MedImmune will collaborate with Johns Hopkins University in both biologics and small-molecule projects.

Merck's new facility for aseptic production in Reinbek, Germany is scheduled to be completed in 2016.

Johnson&Johnson will open a network of partnering offices across the UK.